亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study

医学 曲妥珠单抗 肿瘤科 结直肠癌 内科学 临床终点 队列 中期分析 化疗 瑞戈非尼 癌症 临床试验 乳腺癌
作者
John H. Strickler,Andrea Cercek,Salvatore Siena,Thierry André,Kimmie Ng,Eric Van Cutsem,Christina Wu,Andrew Scott Paulson,Joleen M. Hubbard,Andrew L. Coveler,Christos Fountzilas,Adel Kardosh,Pashtoon Murtaza Kasi,Heinz‐Josef Lenz,Kristen K. Ciombor,Elena Élez,David L. Bajor,Chiara Cremolini,Federico Sanchez,Michael Stecher
出处
期刊:Lancet Oncology [Elsevier BV]
卷期号:24 (5): 496-508 被引量:142
标识
DOI:10.1016/s1470-2045(23)00150-x
摘要

Summary

Background

HER2 is an actionable target in metastatic colorectal cancer. We assessed the activity of tucatinib plus trastuzumab in patients with chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer.

Methods

MOUNTAINEER is a global, open-label, phase 2 study that enrolled patients aged 18 years and older with chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer at 34 sites (clinics and hospitals) in five countries (Belgium, France, Italy, Spain, and the USA). Initially, the study was designed as a single-cohort study, which was expanded following an interim analysis to include more patients. Initially, patients were given tucatinib (300 mg orally twice daily) plus intravenous trastuzumab (8 mg/kg as an initial loading dose, then 6 mg/kg every 21 days; cohort A) for the duration of treatment (until progression), and after expansion, patients were randomly assigned (4:3), using an interactive web response system and stratified by primary tumour location, to either tucatinib plus trastuzumab (cohort B) or tucatinib monotherapy (cohort C). The primary endpoint was confirmed objective response rate per blinded independent central review (BICR) for cohorts A and B combined and was assessed in patients in the full analysis set (ie, patients with HER2-positive disease who received at least one dose of study treatment). Safety was assessed in all patients who received at least one dose of study treatment. This trial is registered with ClinicalTrials.gov, NCT03043313, and is ongoing.

Findings

Between Aug 8, 2017, and Sept 22, 2021, 117 patients were enrolled (45 in cohort A, 41 in cohort B, and 31 in cohort C), of whom 114 patients had locally assessed HER2-positive disease and received treatment (45 in cohort A, 39 in cohort B, and 30 in cohort C; full analysis set), and 116 patients received at least one dose of study treatment (45 in cohort A, 41 in cohort B, and 30 in cohort C; safety population). In the full analysis set, median age was 56·0 years (IQR 47–64), 66 (58%) were male, 48 (42%) were female, 88 (77%) were White, and six (5%) were Black or African American. As of data cutoff (March 28, 2022), in 84 patients from cohorts A and B in the full analysis set, the confirmed objective response rate per BICR was 38·1% (95% CI 27·7–49·3; three patients had a complete response and 29 had a partial response). In cohorts A and B, the most common adverse event was diarrhoea (55 [64%] of 86), the most common grade 3 or worse adverse event was hypertension (six [7%] of 86), and three (3%) patients had tucatinib-related serious adverse events (acute kidney injury, colitis, and fatigue). In cohort C, the most common adverse event was diarrhoea (ten [33%] of 30), the most common grade 3 or worse adverse events were increased alanine aminotransferase and aspartate aminotransferase (both two [7%]), and one (3%) patient had a tucatinib-related serious adverse event (overdose). No deaths were attributed to adverse events. All deaths in treated patients were due to disease progression.

Interpretation

Tucatinib plus trastuzumab had clinically meaningful anti-tumour activity and favourable tolerability. This treatment is the first US Food and Drug Administration-approved anti-HER2 regimen for metastatic colorectal cancer and is an important new treatment option for chemotherapy-refractory HER2-positive metastatic colorectal cancer.

Funding

Seagen and Merck & Co.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
温婉的笑晴完成签到,获得积分20
1秒前
3秒前
所所应助科研通管家采纳,获得10
3秒前
芋头粽子完成签到,获得积分10
6秒前
笑点低的元枫完成签到 ,获得积分10
11秒前
Percy完成签到 ,获得积分10
15秒前
韦老虎发布了新的文献求助30
17秒前
喝可乐的萝卜兔完成签到 ,获得积分10
24秒前
Hung完成签到,获得积分10
25秒前
31秒前
韦老虎完成签到,获得积分20
31秒前
31秒前
Djnsbj发布了新的文献求助10
38秒前
量子星尘发布了新的文献求助10
45秒前
46秒前
黑大侠完成签到 ,获得积分10
47秒前
英姑应助lf采纳,获得10
47秒前
长街发布了新的文献求助20
47秒前
芋头粽子发布了新的文献求助30
49秒前
53秒前
欧皇发布了新的文献求助30
56秒前
lf发布了新的文献求助10
1分钟前
scanker1981完成签到,获得积分10
1分钟前
桐桐应助bbdd2334采纳,获得10
1分钟前
1分钟前
欧皇完成签到,获得积分20
1分钟前
冷傲新柔发布了新的文献求助10
1分钟前
1分钟前
1分钟前
HunterKK7发布了新的文献求助10
1分钟前
轻松的惜芹应助yujie采纳,获得200
1分钟前
沙雕续命完成签到,获得积分10
1分钟前
1分钟前
1分钟前
漂亮采波发布了新的文献求助10
1分钟前
开朗满天发布了新的文献求助10
1分钟前
1分钟前
华仔应助明亮猫咪采纳,获得10
2分钟前
搜集达人应助西域小飞侠采纳,获得10
2分钟前
Ava应助科研通管家采纳,获得10
2分钟前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 700
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3976608
求助须知:如何正确求助?哪些是违规求助? 3520720
关于积分的说明 11204567
捐赠科研通 3257359
什么是DOI,文献DOI怎么找? 1798716
邀请新用户注册赠送积分活动 877897
科研通“疑难数据库(出版商)”最低求助积分说明 806613